SAREPTA THERAPEUTICS INC (1SRPT.MI) Stock Fundamental Analysis
Europe • Euronext Milan • BIT:1SRPT • US8036071004
18.84 EUR
+1.07 (+6.02%)
Last: Jan 27, 2026, 07:00 PM
Taking everything into account, 1SRPT scores 3 out of 10 in our fundamental rating. 1SRPT was compared to 84 industry peers in the Biotechnology industry. 1SRPT has a bad profitability rating. Also its financial health evaluation is rather negative. 1SRPT is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
- 1SRPT had negative earnings in the past year.
- In the past year 1SRPT has reported a negative cash flow from operations.
- In the past 5 years 1SRPT reported 4 times negative net income.
- 1SRPT had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
- The Return On Assets of 1SRPT (-7.77%) is better than 65.48% of its industry peers.
- With a decent Return On Equity value of -20.57%, 1SRPT is doing good in the industry, outperforming 67.86% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -7.77% | ||
| ROE | -20.57% | ||
| ROIC | N/A |
ROA(3y)-10.99%
ROA(5y)-12.97%
ROE(3y)-76.57%
ROE(5y)-69.51%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- 1SRPT has a Gross Margin of 76.25%. This is in the better half of the industry: 1SRPT outperforms 67.86% of its industry peers.
- 1SRPT's Gross Margin has been stable in the last couple of years.
- 1SRPT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 76.25% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.15%
GM growth 5Y-0.45%
2. Health
2.1 Basic Checks
- 1SRPT does not have a ROIC to compare to the WACC, probably because it is not profitable.
- The number of shares outstanding for 1SRPT has been increased compared to 1 year ago.
- 1SRPT has more shares outstanding than it did 5 years ago.
- 1SRPT has a better debt/assets ratio than last year.
2.2 Solvency
- Based on the Altman-Z score of 0.02, we must say that 1SRPT is in the distress zone and has some risk of bankruptcy.
- With a Altman-Z score value of 0.02, 1SRPT perfoms like the industry average, outperforming 51.19% of the companies in the same industry.
- 1SRPT has a Debt/Equity ratio of 0.78. This is a neutral value indicating 1SRPT is somewhat dependend on debt financing.
- 1SRPT has a Debt to Equity ratio (0.78) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.78 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.02 |
ROIC/WACCN/A
WACC7.08%
2.3 Liquidity
- 1SRPT has a Current Ratio of 2.95. This indicates that 1SRPT is financially healthy and has no problem in meeting its short term obligations.
- With a decent Current ratio value of 2.95, 1SRPT is doing good in the industry, outperforming 61.90% of the companies in the same industry.
- A Quick Ratio of 1.79 indicates that 1SRPT should not have too much problems paying its short term obligations.
- 1SRPT's Quick ratio of 1.79 is in line compared to the rest of the industry. 1SRPT outperforms 47.62% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.95 | ||
| Quick Ratio | 1.79 |
3. Growth
3.1 Past
- 1SRPT shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -197.60%.
- Looking at the last year, 1SRPT shows a very strong growth in Revenue. The Revenue has grown by 47.15%.
- Measured over the past years, 1SRPT shows a very strong growth in Revenue. The Revenue has been growing by 37.94% on average per year.
EPS 1Y (TTM)-197.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-102.94%
Revenue 1Y (TTM)47.15%
Revenue growth 3Y39.42%
Revenue growth 5Y37.94%
Sales Q2Q%-14.52%
3.2 Future
- 1SRPT is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 2.98% yearly.
- 1SRPT is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -5.08% yearly.
EPS Next Y-338.34%
EPS Next 2Y6.65%
EPS Next 3Y-4.7%
EPS Next 5Y2.98%
Revenue Next Year14.04%
Revenue Next 2Y-7.99%
Revenue Next 3Y-7.23%
Revenue Next 5Y-5.08%
3.3 Evolution
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for 1SRPT. In the last year negative earnings were reported.
- 1SRPT is valuated reasonably with a Price/Forward Earnings ratio of 8.66.
- Compared to the rest of the industry, the Price/Forward Earnings ratio of 1SRPT indicates a rather cheap valuation: 1SRPT is cheaper than 98.81% of the companies listed in the same industry.
- 1SRPT is valuated cheaply when we compare the Price/Forward Earnings ratio to 25.57, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 8.66 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- A cheap valuation may be justified as 1SRPT's earnings are expected to decrease with -4.70% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y6.65%
EPS Next 3Y-4.7%
5. Dividend
5.1 Amount
- 1SRPT does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
SAREPTA THERAPEUTICS INC / 1SRPT.MI FAQ
What is the fundamental rating for 1SRPT stock?
ChartMill assigns a fundamental rating of 3 / 10 to 1SRPT.MI.
Can you provide the valuation status for SAREPTA THERAPEUTICS INC?
ChartMill assigns a valuation rating of 2 / 10 to SAREPTA THERAPEUTICS INC (1SRPT.MI). This can be considered as Overvalued.
How profitable is SAREPTA THERAPEUTICS INC (1SRPT.MI) stock?
SAREPTA THERAPEUTICS INC (1SRPT.MI) has a profitability rating of 2 / 10.
What is the financial health of SAREPTA THERAPEUTICS INC (1SRPT.MI) stock?
The financial health rating of SAREPTA THERAPEUTICS INC (1SRPT.MI) is 3 / 10.